Study Links BRCA1/2 Germline Mutations to Platinum Drug Response in TNBC

NEW YORK (GenomeWeb) – Results from a study funded by Myriad Genetics, Breast Cancer Now, and Cancer Research UK suggest that the platinum-based, DNA crosslinking chemotherapy drug carboplatin is more apt to benefit triple-negative breast cancer (TNBC) patients who carry cancer-related germline mutations in BRCA1/2 genes.

Source: https://www.genomeweb.com/molecular-diagnostics/study-links-brca12-germline-mutations-platinum-drug-response-tnbc